{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Onsite-Monitoring-Visits-and-Source-Data-Verification”
},
“headline”: “SOP for Onsite Monitoring Visits and Source Data Verification”,
“description”: “This SOP describes procedures for conducting onsite monitoring visits and performing source data verification (SDV) in clinical trials, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP standards.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Onsite Monitoring Visits and Source Data Verification

Purpose

The purpose of this SOP is to define the standardized procedures for conducting onsite monitoring visits and performing Source Data Verification (SDV) in clinical trials. Onsite monitoring ensures participant safety, data integrity, compliance with the protocol, and adherence to ICH GCP, FDA, EMA, CDSCO, and WHO requirements.

Scope

This SOP applies to Clinical Research Associates (CRAs), sponsors, CROs, investigators, and QA personnel involved in trial oversight. It covers preparation, conduct, and follow-up of onsite monitoring visits, as well as verification of source data against Case Report Forms (CRFs) and electronic data capture (EDC) systems.

Responsibilities

• CRA/Monitor: Conducts onsite visits, performs SDV, and documents findings in monitoring reports.
• PI: Ensures site staff facilitate monitoring activities and provides access to source documents.
• Study Coordinator: Prepares essential documents and subject records for CRA review.
• Sponsor/CRO: Defines monitoring visit frequency and ensures timely follow-up on findings.
• QA Officer: Reviews monitoring documentation and audits selected visits.

Accountability

The sponsor is accountable for ensuring monitoring visits are planned and executed. The CRA is accountable for conducting SDV and documenting deviations or discrepancies. The PI is accountable for site compliance and implementation of corrective actions.

Procedure

1. Pre-Visit Preparation
CRA reviews protocol, Investigator Site File (ISF), prior monitoring reports, and site status.
Notify PI and study coordinator at least 2 weeks prior to visit.
Prepare Monitoring Visit Checklist (Annexure-1).

2. Conduct of Onsite Visit
Meet with PI and staff to review site progress and issues.
Verify informed consent process and ensure original signed forms are filed.
Review protocol compliance including visit schedules, dosing, and procedures.
Conduct Source Data Verification (SDV): compare CRF entries with source documents (lab reports, hospital records, AE/SAE notes).
Check drug accountability and investigational product (IP) storage conditions.
Review essential documents including delegation logs, training records, and regulatory binders.

3. Documentation During Visit
Record findings in Monitoring Visit Report (Annexure-2).
Document major deviations, missing data, or inconsistencies.
Discuss preliminary findings with PI at end of visit.

4. Post-Visit Activities
Submit monitoring report within 7 working days.
File report in TMF and ISF.
Ensure CAPA plans are initiated for deviations (Annexure-3).

5. Frequency of Visits
Conduct first monitoring visit within 4 weeks of first subject enrollment.
Subsequent visits scheduled based on enrollment rate, data volume, and risk profile (every 6–8 weeks or as defined in Monitoring Plan).

6. Escalation
Immediate escalation required for critical GCP violations or safety concerns.
Document escalations in Escalation Log (Annexure-4).

7. Archiving
Archive all monitoring visit reports, SDV checklists, CAPA documentation, and escalation logs in TMF.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• CRA: Clinical Research Associate
• CRO: Clinical Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File
• SDV: Source Data Verification
• IP: Investigational Product
• CAPA: Corrective and Preventive Action

Documents

1. Monitoring Visit Checklist (Annexure-1)
2. Monitoring Visit Report (Annexure-2)
3. CAPA Log (Annexure-3)
4. Escalation Log (Annexure-4)

References

• ICH E6(R2) – Good Clinical Practice
• FDA – Guidance on Risk-Based Monitoring
• EMA – Monitoring Clinical Trials
• CDSCO – Monitoring Requirements
• WHO – Onsite Monitoring Recommendations

Version: 1.0

Approval Section

Annexures

Annexure-1: Monitoring Visit Checklist

Annexure-2: Monitoring Visit Report

Annexure-3: CAPA Log

Annexure-4: Escalation Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Monitoring-Plan-Development-RBM-Enabled”
},
“headline”: “SOP for Monitoring Plan Development (Risk-Based Monitoring Enabled)”,
“description”: “This SOP defines procedures for developing a monitoring plan with risk-based monitoring (RBM) strategies in clinical trials. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP expectations for adaptive, data-driven trial oversight.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Monitoring Plan Development (RBM Enabled)

Purpose

The purpose of this SOP is to define the process for developing a monitoring plan in clinical trials, with emphasis on Risk-Based Monitoring (RBM). The monitoring plan provides a structured approach to ensure subject safety, data integrity, and compliance with regulatory requirements, while optimizing monitoring resources through a risk-based strategy.

Scope

This SOP applies to sponsors, CROs, clinical research associates (CRAs), monitors, and investigators involved in planning and executing clinical trial monitoring activities. It covers development of a monitoring strategy, RBM methodology, central monitoring integration, onsite and remote monitoring schedules, escalation procedures, and documentation requirements.

Responsibilities

• Sponsor: Oversees monitoring plan design, approval, and compliance with regulatory requirements.
• Clinical Operations Manager: Develops monitoring strategy, incorporating RBM principles.
• CRA/Monitor: Executes monitoring plan, documents findings, and ensures corrective actions.
• Data Manager: Provides risk metrics and key risk indicators (KRIs) for RBM integration.
• Principal Investigator (PI): Ensures site compliance and facilitates monitoring visits.
• QA Officer: Audits monitoring plans and verifies adherence during inspections.

Accountability

The sponsor is accountable for ensuring that a comprehensive monitoring plan is developed, risk-based elements are integrated, and monitoring activities are aligned with regulatory expectations (ICH GCP E6 R2, FDA guidance, EMA RBM reflection paper).

Procedure

1. Risk Assessment
Conduct trial-level risk assessment before drafting the monitoring plan.
Identify critical data and processes impacting subject safety and data integrity.
Define Key Risk Indicators (KRIs) such as SAE reporting timelines, data entry lag, and protocol deviations.

2. Monitoring Strategy Development
Choose appropriate monitoring model: 100% SDV, targeted SDV, centralized monitoring, or hybrid.
Document rationale for selected strategy in the Monitoring Strategy Log (Annexure-1).

3. RBM Methodology Integration
Incorporate centralized data review dashboards for trend analysis.
Use KRIs and Quality Tolerance Limits (QTLs) to guide monitoring intensity.
Trigger escalations when KRIs exceed predefined thresholds.

4. Monitoring Visit Planning
Define frequency of onsite and remote visits based on risk profile.
Schedule visits proportionally to enrollment, data volume, and site history.
Record planned visits in Monitoring Visit Schedule (Annexure-2).

5. Monitoring Tools and Templates
Use standardized checklists and monitoring report templates.
Ensure all tools are stored in TMF for inspection readiness.

6. Execution and Documentation
CRAs execute visits, review source data, verify CRF entries, and assess protocol compliance.
Findings are documented in Monitoring Visit Reports (Annexure-3).
Serious issues must be escalated to Clinical Operations Manager within 24 hours.

7. Escalation and CAPA
Escalate major protocol deviations, repeated non-compliance, or GCP violations.
CAPA plans must be developed, implemented, and tracked.
Document escalations in Escalation Log (Annexure-4).

8. Review and Updates
Monitoring plan must be reviewed at least annually or when significant protocol changes occur.
Updates must be version controlled and filed in TMF.

9. Archiving
Archive final monitoring plans, reports, logs, and escalations for at least 15 years.
Maintain retrievability for regulatory inspections.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• CRA: Clinical Research Associate
• CRO: Clinical Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File
• RBM: Risk-Based Monitoring
• KRI: Key Risk Indicator
• QTL: Quality Tolerance Limit
• SDV: Source Data Verification

Documents

1. Monitoring Strategy Log (Annexure-1)
2. Monitoring Visit Schedule (Annexure-2)
3. Monitoring Visit Report (Annexure-3)
4. Escalation Log (Annexure-4)

References

• ICH E6(R2) – Good Clinical Practice
• FDA – Guidance on Risk-Based Monitoring
• EMA – Risk-Based Quality Management in Clinical Trials
• CDSCO – Monitoring Requirements for Clinical Trials
• WHO – Monitoring Guidelines in Clinical Research

Version: 1.0

Approval Section

Annexures

Annexure-1: Monitoring Strategy Log

Annexure-2: Monitoring Visit Schedule

Annexure-3: Monitoring Visit Report

Annexure-4: Escalation Log

Revision History

For more SOPs visit: Pharma SOP